ADMA Biologics promotes Kaitlin Kestenberg to COO and SVP, Compliance

ADMA BIOLOGICS, INC.

Kestenberg promoted from SVP, Compliance & Project Operations to COO and SVP, Compliance, effective April 1, 2024.
Base salary of $460,000; annual target bonus of 50% of base salary.
Granted options for 300,328 shares and 192,320 RSUs, each vesting over four years.
Severance includes 12 months salary (or 15 months plus 1.5x bonus upon change of control) plus COBRA.
Kestenberg has been with ADMA since 2011; prior roles at Acorda Therapeutics and Merck.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Kaitlin Kestenberg

Chief Operating Officer and Senior Vice President, Compliance

ADMA · ADMA BIOLOGICS, INC.

Effective: 2024-04-01
Filed: April 2, 2024, 7:59 PM ET

Effective April 1, 2024 (the “Effective Date”), Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc. (the “Company”), was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kaitlin Kestenberg changed role as Chief Operating Officer and Senior Vice President, Compliance at ADMA BIOLOGICS, INC..

Action: promoted
Role: Chief Operating Officer and Senior Vice President, Compliance

Exact text from the filing

Effective April 1, 2024 (the “Effective Date”), Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc. (the “Company”), was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company

View on SEC.gov

ADMA BIOLOGICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-017331

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.